Comparative analysis of the efficacies of entecavir capsules and lamivudine in chronic hepatitis B patients.
- Author:
Dao-zhen XU
1
;
Hao-dong CAI
;
Xiu-yun MA
;
Yue-qi LI
;
Xian-zhong LU
;
Hai-ying YU
;
Ai-min SUN
;
Long-feng ZHAO
;
Liao-yun ZHANG
;
Xiao-hong GAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; Double-Blind Method; Female; Guanine; analogs & derivatives; therapeutic use; Hepatitis B, Chronic; drug therapy; Humans; Lamivudine; therapeutic use; Male; Young Adult
- From: Chinese Journal of Hepatology 2013;21(12):886-890
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the efficacy profile of entecavir capsule (ETV) as a chronic hepatitis B therapy, as compared to lamivudine (LAM).
METHODSIn this multicenter, randomized, double-blind, parallel group evaluation of ETV, 232 subjects were administered a 96-week course of 0.5 mg/day ETV or 100 mg/day LAM. PCR measurement of hepatitis B virus (HBV) was conducted throughout the treatment course to determine achievement of complete virologic response (CVR; defined as less than 500 copies/ml of HBV DNA) or experience of virology rebound ( more than 500 copies/ml of HBV DNA after achievement of CVR).
RESULTSAfter week-48 of treatment, the ETV group showed a higher CVR rate (90.3% vs. LAM: 59.4%) and lower virology rebound rate (1.9% vs. LAM: 13.9%). After week-96 of treatment, the ETV group continued to have a higher CVR rate (86.0% vs. LAM: 71.4%), and virology rebound was experienced by significantly less subjects in the ETV group (1.2% vs. LAM: 11.9%, P = 0.005).
CONCLUSIONETV therapy can quickly and continuously suppress HBV replication in chronic hepatitis B patients, and has a lower resistance rate than LAM. Compared to LAM, ETV may be a superior long-term treatment choice for chronic hepatitis B.
